It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
NK cells are endowed with tumor killing ability, nevertheless most cancers impair NK cell functionality, and cell-based therapies have limited efficacy in solid tumors. How cancers render NK cell dysfunctional is unclear, and overcoming resistance is an important immune-therapeutic aim. Here, we identify autophagy as a central regulator of NK cell anti-tumor function. Analysis of differentially expressed genes in tumor-infiltrating versus non-tumor NK cells from our previously published scRNA-seq data of advanced human prostate cancer shows deregulation of the autophagic pathway in tumor-infiltrating NK cells. We confirm this by flow cytometry in patients and in diverse cancer models in mice. We further demonstrate that exposure of NK cells to cancer deregulates the autophagic process, decreases mitochondrial polarization and impairs effector functions. Mechanistically, CCAAT enhancer binding protein beta (C/EBPβ), downstream of CXCL12-CXCR4 interaction, acts as regulator of NK cell metabolism. Accordingly, inhibition of CXCR4 and C/EBPβ restores NK cell fitness. Finally, genetic and pharmacological activation of autophagy improves NK cell effector and cytotoxic functions, which enables tumour control by NK and CAR-NK cells. In conclusion, our study identifies autophagy as an intracellular checkpoint in NK cells and introduces autophagy regulation as an approach to strengthen NK-cell-based immunotherapies.
NK cells play an important role in anti-tumour immunity, however, the immune-hostile microenvironment often impairs their function. Here authors show that cancers disable autophagy in NK cells, and by restoring this process, intra-tumour NK cells could be re-invigorated.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Iovino, Marta 1 ; Kunderfranco, Paolo 2
; Pandini, Marta 3 ; Marelli, Giulia 1 ; Morina, Nicolò 3 ; Lazzeri, Massimo 4
; Casale, Paolo 4 ; Colombo, Piergiuseppe 5 ; De Simone, Gabriele 6 ; Camisaschi, Chiara 6 ; Lugli, Enrico 6
; Basso, Gianluca 7 ; Cibella, Javier 7 ; Marchini, Sergio 7 ; Bordi, Matteo 8
; Meregalli, Greta 1 ; Garbin, Anna 1 ; Dambra, Monica 9 ; Magrini, Elena 9
; Rackwitz, Wiebke 10 ; Cecconi, Francesco 11 ; Corbelli, Alessandro 12 ; Fiordaliso, Fabio 12
; Eitler, Jiri 13 ; Tonn, Torsten 13
; Di Mitri, Diletta 3 1 Tumor Microenviroment Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
2 Bioinformatics Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
3 Tumor Microenviroment Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807); Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy (GRID:grid.452490.e) (ISNI:0000 0004 4908 9368)
4 Urology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
5 Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
6 Flow Cytometry Core, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
7 Genomics Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
8 Università Cattolica del Sacro Cuore, Department of Basic Biological science, Rome, Italy (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192)
9 Immunopathology Lab, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
10 Dresden University of Technology, Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); German Red Cross Blood Donation Service North-East, Institute for Transfusion Medicine Dresden, Dresden, Germany (GRID:grid.4488.0)
11 Università Cattolica del Sacro Cuore, Department of Basic Biological science, Rome, Italy (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192); Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy (GRID:grid.411075.6) (ISNI:0000 0004 1760 4193)
12 Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Unit of Bio-imaging, Department of Molecular Biochemistry and Pharmacology, Milan, Italy (GRID:grid.4527.4) (ISNI:0000 0001 0667 8902)
13 Dresden University of Technology, Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); German Red Cross Blood Donation Service North-East, Institute for Transfusion Medicine Dresden, Dresden, Germany (GRID:grid.4488.0); Partner Site Dresden, German Cancer Consortium (DKTK), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0004 7865 6683)




